{
  "id": 12598303,
  "title": "BTIG cuts ArriVent BioPharma stock price target on trial results",
  "url": "https://urgent.news/2026/10/07/btig-cuts-arrivent-biopharma-stock-price-target-on-trial-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-07T09:54:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/btig-cuts-arrivent-biopharma-stock-price-target-on-trial-results-93CH-4936012"
  },
  "original_language": "en",
  "account": "BTIG has reduced its price target on ArriVent BioPharma's stock to $29 from $42 while retaining a Buy rating. The firm acknowledged an error in its initial forecast for FURVENT, attributing it to a failure to consider the discrepancy between investigator and baseline control read (BICR) for the chemotherapeutic arm. Discussions with investors now center on a revised entry point and upcoming ARR-217/CDH17 data at ESMO.\n\nDespite a 50% stock decline over the past week, BTIG believes the company is undervalued at present levels. The firm highlights ArriVent's strong financial position, with more cash than debt on its balance sheet. BTIG anticipates a 20% overall response rate (ORR) across doses and 25% ORR at potential future doses in metastatic colorectal cancer (mCRC), which they believe would be viewed positively. Phase 1 data from the company's dual MUC16/NaPi2B antibody-drug conjugate (ADC) may be released as early as next year.\n\nManagement is actively evaluating the pipeline to maximize value and extend cash runway. As of the second quarter of 2026, ArriVent had $373 million in cash, providing runway through 2028. The firm adjusted its model, removing the credit for firmo in exon20ins NSCLC and adding credit for ARR-217 in mCRC, which led to the new $29 price target. BTIG reaffirmed its Buy rating, citing the stock reset and additional opportunities with ARR-217 and the phase 3 ALPACCA trial.\n\nArriVent BioPharma has drawn attention from analysts, with Cantor Fitzgerald maintaining an Overweight rating and H.C. Wainwright raising its price target to $47. The upcoming Phase 1 data from ArriVent's MUC16/NaPi2B ADC and the phase 3 FURVENT trial, which compares firmonertinib with a platinum-based chemotherapy plus pemetrexed in first-line EGFR exon20ins+ NSCLC patients, are expected to drive further investor interest.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}